SRR13780252
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598287 | fetal | fetal | 0.909 |
| 2 | TCGA-MT-A67F-01A-11R-A30B-07 | — | — | 0.893 |
| 3 | BS_5AF6ZNJF | Meningioma | — | 0.883 |
| 4 | 110682 | EPN | Supratentorial EPN | 0.882 |
| 5 | SJEPD032244_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.881 |
| 6 | BS_55JW3HFM | Ganglioglioma | — | 0.874 |
| 7 | SRR608662 | GTEX | — | 0.862 |
| 8 | 20060029.TNBC | — | D | 0.862 |
| 9 | BS_769BDPDB | pilocytic astrocytoma | — | 0.855 |
| 10 | ERR2208891 | — | — | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.610 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.570 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| COMPLEMENT | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| APOPTOSIS | 0.430 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.430 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.250 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |